Core Viewpoint - Visionary Holdings Inc. has signed a strategic cooperation agreement with Jiangsu Yike Regenerative Medical Technology Co., Ltd. to establish a joint venture, Visionary Yike Stemcell Technologies Inc., aimed at advancing stem cell research and commercialization globally [1][5]. Group 1: Joint Venture Details - The joint venture will focus on stem cell therapy, immune cell engineering, and AI-supported anti-aging diagnostics, leveraging Yike's proprietary platform and GV's global market infrastructure [3]. - GV will hold an 85% equity stake in the joint venture, while Yike will hold 15% [3]. - The joint venture aims to create a vertically integrated regenerative medicine enterprise encompassing R&D, trials, manufacturing, and global sales [3]. Group 2: Location and Infrastructure - The headquarters for the joint venture is proposed to be located at GV's property in Toronto, which spans over 40,000 square meters [2]. - The parties are evaluating the feasibility of developing cleanrooms, low-temperature biostorage, and related infrastructures to support future operations [2]. Group 3: Strategic Importance - The establishment of the joint venture is seen as a transformative milestone for GV's global health strategy, with potential for long-term value creation [4]. - This collaboration is expected to enhance GV's positioning in the North American stem cell sector and reflects a commitment to global innovation and shareholder value [5]. Group 4: Company Background - Visionary Holdings Inc. is a technology-driven multinational enterprise focused on innovative education, AI applications, and high-tech healthcare solutions, operating across North America and Asia [6]. - Jiangsu Yike Regenerative Medicine specializes in regenerative medicine and precision anti-aging technologies, holding numerous international patents and certifications [7].

Core Insights - Fountain Life has established a strategic partnership with Celularity to supply stem cell therapy products, leveraging new Florida legislation that allows licensed physicians to administer these therapies without FDA investigational new drug approval [1][2][5] Company Overview - Fountain Life operates four longevity centers in the U.S., including locations in Naples and Lake Nona-Orlando, Florida, with plans to open a new center in Miami [3] - Celularity specializes in regenerative and cellular medicine, focusing on therapies derived from the postpartum placenta, and maintains a substantial inventory of investigational cell therapies at its GMP facility in New Jersey [4][7] Regulatory Framework - The new Florida law, effective July 1, 2025, permits qualified physicians to treat patients with autologous or allogeneic adult stem cell products for specific conditions, including orthopedic issues, wound healing, and pain management [2] - This regulatory change provides a framework for the real-world application of Celularity's placental-based technologies [5] Strategic Alignment - The partnership aligns with Celularity's mission to enhance access to regenerative therapies and supports Fountain Life's commitment to high standards in safety, efficacy, and scalability of regenerative treatments [5][6] - Both companies emphasize a data-driven approach to healthcare, with Fountain Life utilizing advanced AI diagnostics and therapeutics to promote longevity [10]